Published in J Mol Biol on September 01, 2000
Predicting deleterious amino acid substitutions. Genome Res (2001) 28.95
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol (2004) 2.47
HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci (2004) 2.34
Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol (2002) 1.71
Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol (2004) 1.65
Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc Natl Acad Sci U S A (2001) 1.58
Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations. Protein Sci (2002) 1.54
Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J Biol Chem (2008) 1.44
HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc (2008) 1.43
A solution NMR study of the binding kinetics and the internal dynamics of an HIV-1 protease-substrate complex. Protein Sci (2003) 1.39
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. J Virol (2003) 1.37
Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters. FEBS J (2010) 1.30
Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain. J Virol (2005) 1.26
Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev (2008) 1.26
Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. Structure (2007) 1.20
Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. J Virol (2006) 1.15
Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope. J Mol Biol (2011) 1.14
Kinetic characterization of the critical step in HIV-1 protease maturation. Proc Natl Acad Sci U S A (2012) 1.14
ModBase, a database of annotated comparative protein structure models and associated resources. Nucleic Acids Res (2013) 1.12
Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity. J Virol (2006) 1.10
Current and Novel Inhibitors of HIV Protease. Viruses (2009) 1.10
Accurate solution of multi-region continuum biomolecule electrostatic problems using the linearized Poisson-Boltzmann equation with curved boundary elements. J Comput Chem (2009) 1.09
Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease. J Virol (2007) 1.06
HIV-1 protease substrate binding and product release pathways explored with coarse-grained molecular dynamics. Biophys J (2007) 1.05
Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry (2007) 1.03
Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease. Proteins (2008) 0.99
Differential Flap Dynamics in Wild-type and a Drug Resistant Variant of HIV-1 Protease Revealed by Molecular Dynamics and NMR Relaxation. J Chem Theory Comput (2012) 0.98
Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. J Med Chem (2007) 0.97
Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease. ACS Chem Biol (2012) 0.96
Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones. J Med Chem (2010) 0.93
A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant. J Med Chem (2008) 0.92
X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir. J Virol (2007) 0.92
Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci (2005) 0.92
Diversification and specialization of HIV protease function during in vitro evolution. Mol Biol Evol (2006) 0.90
The folding free-energy surface of HIV-1 protease: insights into the thermodynamic basis for resistance to inhibitors. J Mol Biol (2009) 0.88
Novel method for probing the specificity binding profile of ligands: applications to HIV protease. Chem Biol Drug Des (2008) 0.87
A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease. Biochemistry (2011) 0.86
Crystal structure of an HIV assembly and maturation switch. Elife (2016) 0.85
Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease. J Am Chem Soc (2014) 0.85
Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease. Biophys J (2010) 0.85
Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. Chem Biol (2013) 0.84
Highly conserved glycine 86 and arginine 87 residues contribute differently to the structure and activity of the mature HIV-1 protease. Proteins (2010) 0.84
Structure-based prediction of potential binding and nonbinding peptides to HIV-1 protease. Biophys J (2003) 0.83
Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance. Structure (2009) 0.83
Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease. Protein Sci (2012) 0.82
Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease. ACS Chem Biol (2012) 0.82
Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy. Cell Biosci (2012) 0.81
Impact of M36I polymorphism on the interaction of HIV-1 protease with its substrates: insights from molecular dynamics. BMC Genomics (2014) 0.81
Conformational variation of an extreme drug resistant mutant of HIV protease. J Mol Graph Model (2015) 0.80
HIV-1 protease-substrate coevolution in nelfinavir resistance. J Virol (2014) 0.80
Conserved hydrogen bonds and water molecules in MDR HIV-1 protease substrate complexes. Biochem Biophys Res Commun (2012) 0.80
Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease. BMC Bioinformatics (2015) 0.80
Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance. J Med Chem (2012) 0.79
Identification of folding preferences of cleavage junctions of HIV-1 precursor proteins for regulation of cleavability. J Mol Model (2010) 0.79
Modulation of HIV protease flexibility by the T80N mutation. Proteins (2015) 0.77
Mining the protein data bank to differentiate error from structural variation in clustered static structures: an examination of HIV protease. Viruses (2012) 0.76
A Direct Interaction with RNA Dramatically Enhances the Catalytic Activity of the HIV-1 Protease In Vitro. J Mol Biol (2015) 0.76
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med (2000) 7.55
Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 6.27
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med (1994) 5.03
All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1997) 4.79
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 3.19
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res (1998) 2.56
Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med (1995) 2.33
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res (1998) 2.33
Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure (2000) 2.10
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol (1988) 2.06
Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res (1996) 1.99
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood (1999) 1.85
Prophylactic platelet transfusion. Transfusion (1992) 1.61
Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol (1989) 1.54
The effect of lymphocytotoxic antibody reactivity on the results of single antigen mismatched platelet transfusions to alloimmunized patients. Blood (1996) 1.44
Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood (2000) 1.41
Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am J Med (1980) 1.40
A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia. Leukemia (1993) 1.38
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia (2012) 1.37
Storage and transfusion of platelets collected by an automated two-stage apheresis procedure. Transfusion (1992) 1.36
Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol (1997) 1.36
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol (1999) 1.36
Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. N Engl J Med (1986) 1.35
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood (1994) 1.22
Rapid migration of 111indium-labeled granulocytes to sites of infection. N Engl J Med (1981) 1.22
Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol (1987) 1.17
Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. J Natl Cancer Inst (1993) 1.12
Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood (1997) 1.10
Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. Leukemia (1996) 1.04
Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells. Br J Cancer (1995) 1.02
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer Chemother Pharmacol (1995) 1.02
Clinical experience with transfusion of granulocytes obtained by continuous flow filtration leukopheresis. Am J Med (1975) 1.01
Alloimmunization following prophylactic granulocyte transfusion. Blood (1979) 1.01
Asn177 in Escherichia coli thymidylate synthase is a major determinant of pyrimidine specificity. Proc Natl Acad Sci U S A (1992) 1.01
Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. Blood (1987) 1.00
A prospective ophthalmic evaluation of patients with acute myeloid leukemia: correlation of ocular and hematologic findings. J Clin Oncol (1989) 0.99
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol (2001) 0.99
Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA (1980) 0.97
Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia (1998) 0.97
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol (2001) 0.96
Investigation of protein unfolding and stability by computer simulation. Philos Trans R Soc Lond B Biol Sci (1995) 0.96
Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood (1999) 0.95
Fate in humans of the plasticizer, di-2-ethylhexyl phthalate, arising from transfusion of platelets stored in vinyl plastic bags. Transfusion (1976) 0.95
Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia (1998) 0.94
Alloimmunization following platelet transfusion: the absence of a dose-response relationship. Blood (1981) 0.94
The relationship between the duration of platelet storage and the development of transfusion reactions. Transfusion (1998) 0.93
Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. Clin Cancer Res (1998) 0.92
Frozen autologous platelet transfusion for patients with leukemia. N Engl J Med (1978) 0.92
Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic gammadelta T cell lymphoma. Leukemia (1997) 0.92
Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study. Br J Haematol (1998) 0.90
Clinical experience with transfusion of cryopreserved platelets. Br J Haematol (1976) 0.88
Platelet storage for 7 days in second-generation blood bags. Transfusion (1986) 0.88
Myelodysplastic syndromes standardized response criteria: further definition. Blood (2001) 0.87
Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized. Blood (1981) 0.86
ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion (1989) 0.86
Granulocyte transfusions: evaluation of factors influencing results and a comparison of filtration and intermittent centrifugation leukapheresis. Br J Haematol (1978) 0.86
Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B. Semin Oncol (1987) 0.85
Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates. Blood (1992) 0.85
A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood (1983) 0.85
Prevention of alloimmunization against platelets. Blood (1991) 0.85
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol (2000) 0.83
Principles of granulocyte transfusion therapy. Med Clin North Am (1977) 0.83
The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol (1991) 0.82
Clinical evaluation of platelet concentrates stored for one to five days. Blood (1986) 0.81
Clinical and cytogenetic features of familial erythroleukaemia. Br J Haematol (1987) 0.81
Effect of histocompatibility factors on pulmonary retention of indium-111-labeled granulocytes. Am J Hematol (1990) 0.81
Letter: Filtration leukopheresis. Blood (1976) 0.80
Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol (1992) 0.80
Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia. Cancer Treat Rep (1976) 0.80
Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol (1996) 0.80
Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL. Blood (1994) 0.80
Use of a purified heterodimer to test negative cooperativity as the basis of substrate inactivation of Escherichia coli thymidylate synthase (Asn177-->Asp). Structure (1994) 0.80
Sounding board: Platelet transfusions from single donors. N Engl J Med (1982) 0.80
Electrostatic guidance of catalysis by a conserved glutamic acid in Escherichia coli dTMP synthase and bacteriophage T4 dCMP hydroxymethylase. Biochemistry (1995) 0.80
Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients. Blood (1987) 0.79
Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion. Transfusion (1987) 0.79
Antibody response in patients with acute nonlymphocytic leukemia. Cancer (1976) 0.79
Donor selection for alloimmunized patients by platelet crossmatching of random-donor platelet concentrates. Transfusion (1990) 0.79
Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia. Leukemia (1990) 0.79
Incubation of platelet concentrates before transfusion does not improve posttransfusion recovery. Transfusion (1990) 0.79
Some aspects of recent advances in the use of blood cell components. Br J Haematol (1978) 0.79
Unusual karyotypic changes and B cell involvement in a case of lymph node blast crisis of chronic myelogenous leukemia. Blood (1984) 0.78
Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia. Am J Clin Oncol (1990) 0.78
Association of the translocation (15;17) with malignant proliferation of promyelocytes in acute leukemia and chronic myelogenous leukemia at blastic crisis. Blood (1986) 0.78
Carboplatin in previously treated multiple myeloma. A Cancer and Leukemia Group B phase II trial. Am J Clin Oncol (1994) 0.78
Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study. Am J Hematol (1990) 0.78
A clinical program of platelet cryopreservation. Prog Clin Biol Res (1982) 0.78